3970-37-4 Usage
Description
1-Bromo-2-chloro-3-nitrobenzene is an organic compound with the molecular formula C6H3BrClNO2. It is a halogenated nitrobenzene derivative, featuring a bromine atom at the 1st position, a chlorine atom at the 2nd position, and a nitro group at the 3rd position on the benzene ring. 1-BROMO-2-CHLORO-3-NITROBENZENE is known for its reactivity and is commonly utilized as a building block in the synthesis of various organic molecules, particularly in the pharmaceutical industry.
Uses
1. Used in Pharmaceutical Synthesis:
1-Bromo-2-chloro-3-nitrobenzene is used as a reagent in the pharmaceutical industry for the synthesis of various drugs and drug candidates. Its unique structure allows for further functionalization and modification, making it a valuable intermediate in the development of new therapeutic agents.
2. Used in the Synthesis of Benzodiazepinone Bromodomain Inhibitor CPI-?637:
In the field of cancer therapy, 1-bromo-2-chloro-3-nitrobenzene is employed in the synthesis of benzodiazepinone bromodomain inhibitor CPI-?637. Bromodomain inhibitors, such as CPI-?637, are a class of drugs that target specific protein-protein interactions, which play a crucial role in the regulation of gene expression and cellular processes. By inhibiting these interactions, CPI-?637 may have potential applications in the treatment of various types of cancer.
3. Used in the Development of Novel Drug Delivery Systems:
1-BROMO-2-CHLORO-3-NITROBENZENE may also be utilized in the development of innovative drug delivery systems, which aim to improve the bioavailability, targeting, and overall efficacy of therapeutic agents. By incorporating 1-bromo-2-chloro-3-nitrobenzene into the design of these systems, researchers can potentially enhance the delivery of drugs to specific cells or tissues, thereby increasing their therapeutic potential.
Check Digit Verification of cas no
The CAS Registry Mumber 3970-37-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,9,7 and 0 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 3970-37:
(6*3)+(5*9)+(4*7)+(3*0)+(2*3)+(1*7)=104
104 % 10 = 4
So 3970-37-4 is a valid CAS Registry Number.
InChI:InChI=1/C6H3BrClNO2/c7-4-2-1-3-5(6(4)8)9(10)11/h1-3H
3970-37-4Relevant articles and documents
Preparation method 2 - chloro -3 - bromoaniline
-
Paragraph 0022; 0026-0027; 0032; 0036-0037; 0040; 0044-0045, (2021/10/05)
The invention discloses a preparation method of 2 - chloro -3 - bromoaniline, and the specific steps of the preparation method are as follows: (1) the compound II and the bromosuccinimide are subjected to electrophilic substitution reaction to generate the compound III. (2) The sulfonic acid group of the compound III was removed to give compound IV. (3) Compound IV is reduced to compound I with a safety powder, i.e. said 2 - chloro -3 - bromoaniline. To the invention, 4 - chlorine -3 - nitrobenzene sulfonic acid is used as a starting raw material in a full synthetic route process, reagents with large toxicity and large pollution are avoided, and meanwhile, the raw materials are low in price and higher in yield.
SUBSTITUTED QUINAZOLINE COMPOUNDS AND THEIR USE AS INHIBITORS OF G12C MUTANT KRAS, HRAS AND/OR NRAS PROTEINS
-
, (2017/02/09)
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R, R1, R2a, R2b, R2c, A, B, L1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
Compounds and Compositions as Protein Kinase Inhibitors
-
, (2011/04/14)
The present invention provides compounds of Formula I or II: wherein R1, R1b, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds of Formula (I) or (II) and pharmaceutical compositions thereof are useful for the treatment of B-Raf-associated diseases.